Aurinia Pharmaceuticals Approves New Equity Incentive Plan

Aurinia Pharmaceuticals ( (AUPH) ) just unveiled an update.

At the annual general meeting held on May 15, 2025, Aurinia Pharmaceuticals‘ shareholders approved an amended Equity Incentive Plan and revised Bylaws allowing shareholders to set the number of directors. The meeting also resulted in the election of several board members and the approval of PricewaterhouseCoopers LLP as the company’s independent accounting firm. These changes are expected to enhance corporate governance and align executive compensation with shareholder interests.

The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Spark’s Take on AUPH Stock

According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.

Aurinia Pharmaceuticals shows robust financial performance and promising growth in revenue and profitability. The technical analysis is neutral, while the valuation is moderate. Positive earnings call highlights provide confidence, despite legal and regulatory risks. The overall outlook is optimistic, but investors should monitor ongoing challenges.

To see Spark’s full report on AUPH stock, click here.

More about Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for autoimmune diseases. The company is known for its work on treatments targeting lupus nephritis and other related conditions.

Average Trading Volume: 1,439,335

Technical Sentiment Signal: Hold

Current Market Cap: $1.06B

See more data about AUPH stock on TipRanks’ Stock Analysis page.